These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer.
    Author: Fowler M.
    Journal: Oncology (Williston Park); 2020 Jul 15; 34(7):250. PubMed ID: 32674207.
    Abstract:
    Mirvetuximab soravtansine in combination with bevacizumab (Avastin) to treat patients with platinum-agnostic ovarian cancer demonstrated a confirmed 64% overall response rate (ORR), regardless of platinum status, according to study results presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program.
    [Abstract] [Full Text] [Related] [New Search]